MNK News 88.82 09/22/2014 05:16:50 Mallinckrodt Plc Ordinary

New Post Public Reply Private Reply Replies (0) Message Board

Sep 22, 2014 at 6:16 AM

Mallinckrodt Plc Ordinary Share (MNK) 88.82 $MNK

Mallinckrodt (MNK) Highlighted As Momo Momentum Stock
at The Street - Fri Sep 19, 9:14AM CDT
Trade-Ideas LLC identified Mallinckrodt (MNK) as a momo momentum candidate

Impax Rytary FDA Action Date Extended by Three Months - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 3:30PM CDT
The FDA has pushed back the PDUFA date for Impax Laboratories, Inc.'s Rytary by three months to Jan 9, 2015.

Alcobra (ADHD) Worth Watching: Stock Moves 5.1% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:25AM CDT
Alcobra (ADHD) was a big mover last session, with shares rising over 5% on the day.

Novo Nordisk's Tresiba Effective in Children & Adolescents - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 5:10PM CDT
Novo Nordisk (NVO) announced new positive data from the BEGIN YOUNG 1 study on Tresiba for type I diabetes in children and adolescents (1 year to <18 years).

Earnings, Market Activity, Investment Agreements, Study Data, and Product Deployment - Research Reports on Darden, XPO, Mallinckrodt, SJM and Honeywell
PR Newswire - Wed Sep 17, 7:40AM CDT
Today, Analysts Review released its research reports regarding Darden Restaurants, Inc. (NYSE: DRI), XPO Logistics, Inc. (NYSE: XPO), Mallinckrodt PLC (NYSE: MNK), St. Jude Medical Inc. (NYSE: STJ) and Honeywell International Inc. (NYSE: HON). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6529-100free.

NPS Pharmaceuticals' Natpara Gets Positive FDA Panel Vote - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 6:05PM CDT
The EMDAC of the FDA recommended the approval of NPS Pharmaceuticals' Natpara.

Can Mallinckrodt public limited (MNK) Keep the Earnings Streak Alive This Quarter? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 7:54AM CDT
Mallinckrodt public limited could be a great candidate for another beat after a solid performance in the last two quarters.

Mylan to Acquire U.S. Rights to Arixtra for up to $300M - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 4:20PM CDT
Mylan (MYL) is all set to acquire the U.S. commercialization, marketing and intellectual property rights to Arixtra injection from Aspen.

Actavis' Bystolic Combination Gets Negative FDA Panel Vote - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 3:45PM CDT
Actavis plc (ACT) announced that the FDA's CRDAC has voted against the approval (in the ratio of 6:4) of Actavis' fixed-dose combination (FDC) of Bystolic (nebivolol) and Novartis' (NVS) Diovan (valsartan).

Emergent BioSolutions Wins $29M Anthrax Vaccine Deal - Analyst Blog
Maharathi Basu - Zacks Investment Research - Wed Sep 10, 3:30PM CDT
Emergent BioSolutions (EBS) secured a federal contract worth up to $29 million.

Endocyte (ECYT) Worth Watching: Stock Soars 17% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 8:46AM CDT
Endocyte (ECYT) was a big mover last session, with shares rising just over 17% on the day.

Actavis' Antibiotic under FDA Review, Response in 1Q15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:20PM CDT
Actavis plc (ACT) announced the acceptance of its new drug application for its antibiotic candidate, ceftazidime-avibactam, by the FDA.

Mallinckrodt (MNK) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 9:39AM CDT
Mallinckrodt (MNK) Shares March Higher, Can It Continue?

Technical Snapshot on Pharma Stocks - Allergan, Akorn, Mallinckrodt, Mylan, and AVANIR Pharma
PR Newswire - Mon Sep 08, 8:25AM CDT
On Friday, September 5, 2014, the NASDAQ Composite ended at 4,582.90, up 0.45%, the Dow Jones Industrial Average advanced 0.40%, to finish the day at 17,137.36, and the S&P 500 closed at 2,007.71, up 0.50%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 741.23, up 0.57%, with the index also advancing 6.70% in the last three months. Investor-Edge has initiated coverage on the following equities: Allergan Inc. (NYSE: AGN), Akorn Inc. (NASDAQ: AKRX), Mallinckrodt PLC (NYSE: MNK), Mylan Inc. (NASDAQ: MYL), and AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR). Free research on these five companies can be accessed at:

IntelliPharmaCeutics (IPCI) in Focus: Stock Gains 15.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 8:25AM CDT
IntelliPharmaCeutics (IPCI) was a big mover last session, with shares rising nearly 16% on the day.

New Center, Clinical Study Results, Collaborations, and Upcoming Event - Research Reports on Centene, Mallinckrodt, Infinity, Celgene and UnitedHealth
PR Newswire - Mon Sep 08, 7:55AM CDT
Today, Analysts Review released its research reports regarding Centene Corp. (NYSE: CNC), Mallinckrodt PLC (NYSE: MNK), Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Celgene Corporation (NASDAQ: CELG) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6280-100free.

New REMS Education Program Helps Increase Safe, Responsible Use of Opioid Analgesics for Pain Relief
Business Wire - Mon Sep 08, 7:01AM CDT
Assessments of a novel Continuing Medical Education (CME) initiative showed meaningful changes in opioid prescribing behavior and improvements in pain-patient outcomes. These assessments of REMEDIES (Risk Evaluation and Mitigation Strategies - An Employer-Driven CME Initiative for Efficacy and Safety) - were presented this past week at PAINWeek, the nation's largest conference for clinicians with an interest in pain management.

Mallinckrodt's Pain Therapy Hits Phase III Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 4:05PM CDT
Mallinckrodt plc (MNK) announced encouraging results from a phase III efficacy study on its pain candidate, MNK-155.

Mallinckrodt Pharmaceuticals Presents 11 Posters with Data on Investigational Opioid, MNK-155, and XARTEMIS(TM) XR (oxycodone hydrochloride and acetaminophen) Extended Release Tablets (CII) at PAINWeek 2014
Business Wire - Fri Sep 05, 8:00AM CDT
Mallinckrodt (NYSE: MNK) presented 11 posters with data on its investigational opioid, MNK-155, an extended-release oral formulation of hydrocodone and acetaminophen, and recently FDA-approved XARTEMIS XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII), at PAINWeek, September 2-6 in Las Vegas, Nevada. The studies examined the compound's efficacy, safety, abuse-related characteristics and release/delivery profiles with immediate- and extended-release components.

Actavis' Gastrointestinal Drug Under FDA Priority Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 3:30PM CDT
Shares of Actavis plc (ACT) were up 0.9% after the company announced that the FDA has granted priority review status to its New Drug Application (NDA) for its gastrointestinal candidate, eluxadoline.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ASTS Fraud Lawsuit: Investors' Chance to Step Up

Investors Grapple with AST SpaceMobile's Legal Challenges When I hear 'securities fraud lawsuit,' my gut instinct as a trader is to dig deep into the grime and figure out what's lurking beneath. AST SpaceMobile, those folks aiming to shake up the satellite game, have some explaining to do. If you've been holding onto ASTS shares between March 4, 2025, and July 15, 2026,...

LAZ Parking and indiGOtech's Bold EV Charging Move

EV Chargers: The Future Parked Closer? I've been around the block more times than a cabbie in Manhattan rush hour, and let me tell you, when it comes to EVs, folks are still playing catch-up. But here's a kicker—LAZ Parking and indiGOtech have decided they're not gonna wait around. This joint venture of theirs aims to sock some sense into the old condo complex parking...

Brown Plus Ranks #8 Best Workplace for Women 2026

Cracking the Top Ten: A Noteworthy Feat When it comes to hustling and bustling in the corporate world, Brown Plus managed to snag the spotlight by landing the #8 spot in the 'Best Place to Work for Women 2026.' It's a title they didn't just stumble upon. This recognition in the medium category by the Best Companies Group underscores the fact that Brown Plus is running its...

Tumor Ablation Market: Charting a Billion-Dollar Surge

Cancer's Unforgiving Climb: Opportunity Amidst Challenge Looking at the current state of the global tumor ablation market, one thing's clear—it's on a sort of upward swing you'd expect trains to make, riding the rails of rising cancer rates and technological advancements. At least that's what the folks at Wissen Research are banking on, projecting a leap to $1.8 billion...

Purlin's Patent: Transforming Real Estate Deals

Purlin's Game-Changer: A Patent in Real Estate Real estate has been chugging along like a stubborn mule, dragging deals through opaque negotiations and haphazard guessing games. Then enters Final Offer from Purlin Enterprises, waving a newly granted patent like a shiny golden ticket to those stuck trading homes in the dark. Leveling the Playing Field with Transparency In...

Artificial Stone Silicosis: A Silent Threat Unveiled

The Harsh Reality Behind Artificial Stone You're slicing into your steak at a fancy dinner, and for a moment, you marvel at the countertop beneath your dish—a smooth, sleek surface that's likely made of artificial stone. But beneath that lustrous facade lurks a silent killer affecting those fabricating these countertops every day. Voices from the Frontline Recently,...

Navigating Braces vs. Invisalign: Key Considerations

Choice Between Braces and Invisalign Isn't Straightforward When you're pondering over whether to go with braces or Invisalign, it ain't just a choice you make lightly over coffee. It's a nuanced decision that hinges on a multitude of factors as highlighted by orthodontic experts Dr. Erik Higginbottom and Dr. Kyle Higginbottom from Easton, MD, featured in HelloNation's...

Alaska LNG Project Boosted by Strategic Positioning

Alaska LNG: Right Place, Right Time Someone bring out the confetti, because Paul Sullivan, Co-Chairman of Gastech, is celebrating Alaska LNG like it's 1999. And for good reason. If Alaska ever played its cards right, now's the moment according to the industry veteran. After Gastech 2026 wrapped its events in Bangkok last month, Sullivan laid out why the stars are aligning...

LBT Unveils Game-Changing Cyclotron for Medical Advances

Unveiling the LB-30 Cyclotron at EANM 2026 Life in nuclear medicine never stands still, and once again, Longevous Beamtech (LBT) is stirring the pot with its brand-new LB-30 series medical cyclotron. They rolled out this high-powered beast at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM 2026) in Vienna. Leaning into the 30 MeV energy...

Spooky Suds: House of Horror Meets El Car Wash

A Haunted Wash Awaits Miami Drivers Picture this: you're cruising down West Flagler on a regular Wednesday evening, but tonight, you're not just rolling in for a rinse. Nope, this Wednesday night, the wash tunnel at El Car Wash gets downright spooky. It's getting a haunted house makeover with scare actors from the House of Horror. When a Car Wash Becomes a Haunted...